Index | Marvel Biosciences
Lead by proven industry experience, Marvel is at the forefront of modern science.| Marvel Biosciences
Calgary, Alberta – August 18, 2025 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), , a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced that the China National Intellectual Property Administration (CNIPA) has granted patent number ZL202180020893.4, titled “Purine Compounds for Treating Disorders”....| Marvel Biosciences
Lead by proven industry experience, Marvel is at the forefront of modern science.| Marvel Biosciences
Calgary, Alberta, Canada, August 11, 2025 – Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 142,987 deferred share units (“DSUs”) to two of Marvel’s directors, in lieu of cash payment for directors’ fees.| Marvel Biosciences
The post Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment appeared first on Marvel Biosciences.| Marvel Biosciences
The post Marvel Biosciences to Give Oral Presentation at the Annual IRSF Rett Syndrome Scientific Meeting appeared first on Marvel Biosciences.| Marvel Biosciences
[et_pb_section fb_built=”1″ _builder_version=”3.22″ custom_padding=”15px|||||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”7px|auto||auto||” custom_padding=”0px|||||” global_colors_info=”{}” theme_builder_area=”post_content” min_height=”1746.2px”][et_pb_column type=”4_4″ _builder_version=...| Marvel Biosciences
[et_pb_section fb_built=”1″ _builder_version=”3.22″ custom_padding=”15px|||||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”7px|auto||auto||” custom_padding=”0px|||||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=...| Marvel Biosciences
The post Marvel Biosciences to File for Orphan Drug Designation with the U.S. FDA for MB-204 as a Treatment for Rett Syndrome appeared first on Marvel Biosciences.| Marvel Biosciences
The post Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide appeared first on Marvel Biosciences.| Marvel Biosciences
Calgary, Alberta – March 11, 2025 – Marvel Biosciences Corp. (TSXV: MRVL OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today is pleased to announce it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Centre, on May 5 and 6, 2025.| Marvel Biosciences
The post Marvel Biosciences Announces Notice of Allowance of Composition of Matter Patent for Its Lead Molecule MB-204 in China appeared first on Marvel Biosciences.| Marvel Biosciences
